anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In France, the overall prevalence of diabetes was estimated at 5% of population in 2016, type 2 diabetes (T2DM) corresponding to 90% of cases. However, this figure is greatly underestimated. since it does not take into account people who are untreated or not diagnosed. However, given the silent nature of the disease, it is estimated that 20 to 30% of adults with diabetes do not are not diagnosed. This share decreases with age, falling to 13% among 55-74 year olds. Conclusions presented during the annual meeting of the european Association for the Study of diabetes (EASD-Berlin) from 2019 suggest that signs precursors of the disease would be present up to 20 years before the diagnosis.

Type 2 diabetes, or non-insulin dependent diabetes, is a metabolic disease characterized by a chronic excess of sugar in the blood, affecting both men and women. the Diagnosis is usually made around 40-50 years. The main factor of risk of T2D is the lifestyle, in particular a diet too rich for a too sedentary daily life. The direct consequences are an increase in obesity hich is itself a major risk factor for the development of T2D. Among the risk factors, we also find hyperlipidemia, high blood pressure, high blood sugar fasting, stress, smoking, heredity, family history of diabetes, or gestational diabetes.

From a medico-economic point of view, chronic pathologies (including diabetes) account for 60% of insurance expenditure illness even though they concern 35% of insured persons, i.e. 20 million patients. The average annual repayment of a type 2 diabetic patient is 4890 euros.This study is part of this context as the starting point a reflection on a different, coordinated management, to know a preventive rather than a curative approach.
Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
Rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with fluvastatin and other drugs in this class. 

Fluvastatin capsules should be prescribed with caution in patients with predisposing factors for myopathy. These factors include advanced age (> 65 years), renal impairment, and inadequately treated hypothyroidism. 

The risk of myopathy and/or rhabdomyolysis with statins is increased with concurrent therapy with cyclosporine, erythromycin, fibrates or niacin. Myopathy was not observed in a clinical trial in 74 patients involving patients who were treated with fluvastatin together with niacin. Isolated cases of myopathy have been reported during postmarketing experience with concomitant administration of fluvastatin and colchicine. No information is available on the pharmacokinetic interaction between fluvastatin and colchicine. 

Uncomplicated myalgia has also been reported in fluvastatin-treated patients [see Adverse Reactions (6)]. In clinical trials, uncomplicated myalgia has been observed infrequently in patients treated with fluvastatin at rates indistinguishable from placebo. Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in CPK values to greater than 10 times the upper limit of normal, was < 0.1% in fluvastatin clinical trials. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. 

All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing fluvastatin.

Fluvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Fluvastatin therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of renal failure secondary to rhabdomyolysis, e.g., sepsis; hypotension; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy.
In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.
ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to \<18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to \<9 kg = 1 tablet once daily for 3 days, 9 to \<18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.
CHCs, such as NEXTSTELLIS, are contraindicated for use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir) [see Contraindications (4)]. Discontinue NEXTSTELLIS prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir (with or without dasabuvir). NEXTSTELLIS can be restarted approximately 2 weeks following completion of treatment with this hepatitis C combination drug regimen.

During clinical trials with the above-mentioned Hepatitis C combination drug regimen, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in females using ethinyl estradiol (EE)-containing drugs, such as CHCs. Females using medications containing estrogens other than EE had a rate of ALT elevation similar to those not receiving any estrogens. NEXTSTELLIS contains E4 rather than EE, but as no data are available for co-administration with this Hepatitis C combination drug regimen, caution is warranted.
BACKGROUND: Pseudomonas aeruginosa is a common pathogen causing healthcare-associated infections. Most surveillance studies from Saudi Arabia that assessed the resistance by P. aeruginosa were conducted in single centers or did not use broth microdilution (BMD), the gold standard test. This is the first national multicenter study to assess the resistance profiles of P. aeruginosa isolates in Saudi Arabia using BMD.
METHODS: Between 2022 and 2023, isolates from various infection sites were collected from seven hospitals in seven different regions of Saudi Arabia. The isolates were shipped to an academic microbiology lab, where their susceptibility was tested by BMD following Clinical Laboratory Standards Institute guidelines using Sensititre GNX3F plates. %Susceptibility to each antibiotic, and MIC50 and MIC90 were determined.
RESULTS: In total, 185 P. aeruginosa isolates were collected. Most isolates came from respiratory specimens (34.1%), followed by urine (21.1%) and skin/soft tissue (17.8%). The highest susceptibility was to amikacin (76.8%). Concurrently, susceptibility to meropenem was 52%, but it was 43.8% to colistin. While all P. aeruginosa isolates met the definition of multidrug-resistance, 41 (22.2%) were difficult-to-treat and 10 (5.4%) were pandrug-resistant. Difficult-to-treat isolates made up 30.3% of skin and soft tissue isolates, 25.4% of respiratory isolates, 21.7% of blood isolates, and 17.9% of urine isolates.
CONCLUSION: Pseudomonas aeruginosa demonstrated an unexpectedly high level of resistance to several commonly used antibiotics. Therefore, antimicrobial stewardship and infection control policies should be strictly enforced by hospitals across the country to optimize treatment, prevent the emergence and spread of resistant strains, and track resistance trends with local antibiograms.
Absorption: After intramuscular administration of 10 mg of progesterone in oil, maximum plasma concentrations (geometric mean of 7 ng/mL) were reached within approximately 8 hours after injection and plasma concentrations remained above baseline for about 24 hours after injection. Injection of 10, 25, and 50 mg resulted in geometric mean values for maximum plasma concentration (CMAX) of 7, 28, and 50 ng/mL, respectively.

Distribution: Progesterone is extensively bound to plasma proteins, primarily albumin (50-54%) and cortisol-binding protein (43-48%).

Metabolism: Progesterone is metabolized primarily in the liver by reduction to pregnanediol, pregnanetriol, and pregnanolone. Subsequent conjugation results in the formation of glucuronide and sulfate metabolites. The mean plasma metabolic clearance rate in cycling women is 2510 ± 135 (SEM) L/day.

Excretion: The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the urine and bile. Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces.

The pharmacokinetic data was determined in a small number of patients, limiting the precision in which population values may be estimated.
<P>PROBLEM TO BE SOLVED: To obtain an external preparation for skin containing one or more kinds of skin elasticity ameliorants selected from active ingredients for providing the skin with firmness and moisture, especially a cosmetic which has excellent feels (elasticity, emollient feeling, spread and moisture retaining property) in use and improved stability with time, especially a massage cream.  <P>SOLUTION: The external preparation for skin contains one or more kinds of skin elasticity ameliorants selected from active ingredients which have no adverse effect, are stable and safe and provide the skin with firmness and moisture. The skin care preparation contains the skin elasticity ameliorant and/or one or more kinds of essential components. The external preparation for skin provides a cosmetic which has excellent feels (elasticity, emollient feeling, spread and moisture retaining property) in use and improved stability with time, especially a massage cosmetic. The cosmetic is widely useful in various technical fields such as medicines, foods, etc., not to mention the field of cosmetic and has excellent effect of achieving the purpose of the invention.  <P>COPYRIGHT: (C)2004,JPO
Placebo group will be treated with detuned photobiomodulation device (904Nm Ibramed Infrared - no-visible beam), without any emission of therapeutic dose. Nine sites will be applicate on the patient's lumbar region: three central sites on top of the spinous processes (between T11 and T12, L2 and L3, L5 and S1); in the same direction, but laterally, three sites on the left and three on the right. Three minutes of fake stimulation will be administered, summing up 27 minutes. In addition, a neutral talking control therapy of at least 15 minutes will be provided to patients in each session. Maladaptive beliefs will not be challenged; however, the therapists will be trained to show interest and warmth, empathy and encouraging participants to discuss neutral topics such as hobbies, sports, and current affairs. No advice or problem solving will be given, and any attempt to talk about emotional issues will be kindly discouraged and the talking will be redirect to neutral tropics.
A mouth and nose occluded detecting method includes a detecting step and a warning step. The detecting step includes a facial detecting step, an image extracting step and an occluded determining step. In the facial detecting step, an image is captured by an image capturing device, wherein a facial portion image is obtained from the image. In the image extracting step, a mouth portion is extracted from the facial portion image so as to obtain a mouth portion image. In the occluded determining step, the mouth portion image is entered into an occluding convolutional neural network so as to produce a determining result, wherein the determining result is an occluding state or a normal state. In the warning step, a warning is provided according to the determining result.
BACKGROUND: Medially stabilised total knee replacement systems aim to provide a more natural feeling knee replacement by providing increased stability through flexion. The aim of this study was to compare the kinematics and wear of two different medially stabilised total knee replacement systems in an experimental simulation study. The Medial Rotation Knee™ system (MRK) is an early medially stabilised knee (>20 years clinical success); the SAIPH® knee system being a more modern and refined, bone conserving evolution of the original design with a larger size range.
METHODS: Three SAIPH and three MRK total knee replacements (MatOrtho Ltd, UK) were investigated. The study was performed on a knee simulator with load controlled input kinematic conditions (ISO 14243-1). 6 million cycles of simulation were carried out with the wear of the UHMWPE tibial components assessed gravimetrically. The resulting anterior-posterior translation and tibial rotation position was measured throughout the study.
RESULTS: The mean UHMWPE wear rate was 0.57 ± 0.71 and 1.24 ± 2.0 mm3/million cycles for SAIPH and MRK total knee replacement systems respectively with no significant difference in wear (p = 0.24). Analysis of simulator output kinematics showed a larger range of anterior-posterior motion for SAIPH total knee replacements compared to MRK. The magnitude of tibial rotation was low for both knee replacement systems.
CONCLUSION: The small magnitude of anterior-posterior displacement and tibial rotation motion demonstrates the inherent stability of this knee system design offered by the constrained medial compartment. This study shows the potential for medially stabilised knee systems as a low polyethylene surface wear solution.
In this arm participants will complete a variety of baseline assessments then participate in 15-20 minute conversation based on motivational interviewing principles in which they are trained in shame resilience. Follow-ups will be conducted a month later. Assessments will be repeated and then participants will engage in a qualitative interview regarding the training.
PURPOSE: To provide powder contg. Plantaginis Semen particles which exhibits excellent dispersibility and is usable as a laxative and fiber supplement by coating the particles of Plantaginis Semen having a capacity to be substantially expanded when taken in with gum arabic. CONSTITUTION: The Plantaginis Semen particles are prepd. and a fluidized bed is formed by fluidizing the Plantaginis Semen particles with air. An effect. amt. of an aq. soln. of the gum arabic is then prepd. and the many droplets of this aq. soln. are added to the fluidized bed to coat the particles with the aq. gum arabic soln. The Plantaginis Semen particles coated with the gum arabic are usable as the laxative and more particularly constipation therapeutic medicine and fiber supplement and may be rapidly dispersed. The Plantaginis Semen particles are recommended to be coated with the gum arabic soln. so as to be uniformly distributed with the gum arabic soln. The coating is preferably so executed that the powder having such grain size distribution, moisture and bulk density as to improve the water dispersibility of the Plantaginis Semen.
Tonsillectomy is the most common surgical procedure performed by otolaryngologists with or without adenoidectomy. \[1\] The most important complication of tonsillectomy is post-tonsillectomy hemorrhage with potential morbidity and death. \[2\] Also, severe pain and wound healing remain major problems that affect patients profoundly after surgery causing a lot of time to return to a regular diet and normal activity. \[3\] Pharmacological drugs are used to control post-tonsillectomy pain but with challenges like insufficiency to control pain, the presence of contraindications, and the presence of side effects as the antiplatelet effects of NSAIDs lead to increased rates of postoperative hemorrhage.\[4\] Growth factors and other mediators released by activated platelets play an important role in tissue regeneration and revascularization. Platelet concentrates, therefore, represent a promising therapeutic tool for tissue regeneration. In recent years, the effects of platelet-rich fibrin (PRF) on tissue healing have been addressed in many surgical branches, especially for dental implant surgery and plastic surgery.\[5\] Injectable platelet-rich fibrin (IPRF) is a recently developed leukocyte-enriched platelet concentrate, which could better assist tissue regeneration and wound healing phenomena. Although initially in a liquid phase, IPRF forms a dynamic fibrin gel embedding platelets, leukocytes, type 1 collagen (COL1), osteocalcin (OC), growth factors, and providing a slow release of growth factors. \[6-10\]
The invention, relating to the technical field of medicine, provides a Chinese-medicinal compound lotion for treating dermatitis eczema and a preparation method thereof. The component proportion of the lotion is: 50-70g of sophora flavescens, 40-60g of common cnidium fruit, 20-40g of phellodendron, 25-35g of Chinese angelica, 15-25g of Ligusticum wallichii, 15-30g of rheum officinale, 3-6g of borneol, and 0.1wt% of antiseptic ethylparaben. The preparation method comprises the following steps: 1) preparing an extract of sophora flavescens, common cnidium fruit and phellodendron; 2) preparing an extract of Chinese angelica, Ligusticum wallichii and rheum officinale; 3) mixing the extracts obtained by step 1) and 2), adding borneol according to the proportion and 0.1wt% of antiseptic ethylparaben, adding water until the amount of the mixture reaches to 1000ml for dilution, and sub-packaging. The lotion can avoid the irritation on gastrointestinal tracts by oral administration, reduce the blood concentration of body and reduce side effects through the transdermal drug delivery. The preparation method is simple, and the lotion is easy to operate and improves the compliance of medicine. The invention provides a novel medicinal preparation for treating dermatitis eczema.
Participants will receive cobimetinib capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D.Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
The present invention is drawn to adhesive peel-forming formulations for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a peel-forming agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the non-volatile solvent system has a solubility for the drug that is within a window of operable solubility for the drug such that the drug can be delivered at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified peelable layer after at least a portion of the volatile solvent system is evaporated. ® KIPO & WIPO 2007
Participants in the MS INFoRm group will be given a login and password that will take them to the MS INFoRm webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
Two 18-month studies were performed in mice to evaluate the carcinogenic potential of fluticasone propionate when given topically (as an 0.05% ointment) and orally. No evidence of carcinogenicity was found in either study.

Fluticasone propionate was not mutagenic in the standard Ames test, E. colifluctuation test, S. cerevisiaegene conversion test, or Chinese Hamster ovarian cell assay. It was not clastogenic in mouse micronucleus or cultured human lymphocyte tests. 

In a fertility and general reproductive performance study in rats, fluticasone propionate administered subcutaneously to females at up to 50 mcg/kg per day and to males at up to 100 mcg/kg per day (later reduced to 50 mcg/kg per day) had no effect upon mating performance or fertility. These doses are approximately 15 and 30 times, respectively, the human systemic exposure following use of the recommended human topical dose of fluticasone propionate cream, 0.05%, assuming human percutaneous absorption of approximately 3% and the use in a 70-kg person of 15 g/day.
Aquatic exercise program including trunk stabilization, upper body, lower body strengthening and flexibility exercises and aerobic conditioning. Supervised 10-week program, 2 times a week.
Recent evidence has shed light on the significant role of FANCD2 in cancer initiation, development, and progression. However, a comprehensive pan-cancer analysis of FANCD2 has been lacking. In this study, we have conducted a thorough investigation into the expression profiles and prognostic significance of FANCD2, as well as its correlation with clinicopathological parameters and immune cell infiltration, using advanced bioinformatic techniques. The results demonstrate that FANCD2 is significantly upregulated in various common cancers and is associated with prognosis. Notably, higher expression levels of FANCD2 are linked to poor overall survival, as indicated by Cox regression and Kaplan-Meier analyses. Additionally, we have observed a decrease in the methylation of FANCD2 DNA in some cancers, and this decrease is inversely correlated with FANCD2 expression. Genetic alterations in FANCD2 predominantly manifest as mutations, which are associated with overall survival, disease-specific survival, disease-free survival, and progression-free survival in certain tumor types. Moreover, FANCD2 exhibits a strong correlation with infiltrating cell levels, immune checkpoint genes, tumor mutation burden (TMB), and microsatellite instability (MSI). Enrichment analysis further highlights the potential impact of FANCD2 on Fanconi anemia (FA) pathway and cell cycle regulation. Through this comprehensive pan-cancer analysis, we have gained a deeper understanding of the functions of FANCD2 in oncogenesis and metastasis across different types of cancer.
Stage 2: AGN-150998 4,2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
PURPOSE:The titled pharmaceutical, containing a high-molecular weight drug in a silicone elastomer and capable of substainedly releasing a very small amount with a low content of the drug for a long time. CONSTITUTION:A sustained release pharmaceutical containing a high-molecular weight drug (1000-500000 molecular weight) in a silicone elastomer, preferably dimethylpolysiloxane expressed by formula I (n is 100-5000; R is methyl, hydroxy or vinyl) or methylvinylpolysiloxane expressed by formula II (n is 100-10000; m is 1-100). A drug, having high activity in a vety small amount and preferably administered sustainedly for a long time is suitable for the high- molecular weight drug and examples thereof include a drug having growth regulating action, e.g. growth hormone, somatomedin, etc., drug having action related to bone metabolism, e.g. calcitonin, drug having thrombolytic action, e.g. tissue plasminogen activating factor, drug having immunological regulatiang action, e.g. interferon, interleukin-2, etc.